Management of atrial fibrillation: discrepancy between guideline recommendations and actual practice exposes patients to risk for complications
about
sameAs
Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillationOccurrence and quality of anticoagulant treatment of chronic atrial fibrillation in primary health care in Sweden: a retrospective study on electronic patient recordsManaging anticoagulation for atrial fibrillation: current issues and future strategiesPharmacoeconomics of anticoagulation therapy for stroke prevention in atrial fibrillation: a reviewManagement of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events--European Registry in Atrial Fibrillation (PREFER in AF)Intensive insulin therapy in intensive care: an example of the struggle to implement evidence-based medicine.Edoxaban: an update on the new oral direct factor Xa inhibitor.Management of atrial fibrillation by primary care physicians in Germany: baseline results of the ATRIUM registryFirst Dutch experience with percutaneous left atrial appendage transcatheter occlusionA practical approach to the management of patients with atrial fibrillation.Underutilization of Warfarin Therapy in Elderly Patients with Atrial Fibrillation - Fear or False Sense of Security!The impact of warfarin use on clinical outcomes in atrial fibrillation: a population-based study.The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management.Use of oral anticoagulation therapy in atrial fibrillation after stroke: results from a nationwide registry.Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review.Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective.A prospective study investigating the causes of warfarin under-utilization in Chinese patients.The pharmacokinetics of darexaban are not affected to a clinically relevant degree by rifampicin, a strong inducer of P-glycoprotein and CYP3A4.Atrial fibrillation: what can we do, what should we do, and what must we do?The prestroke use of vitamin K antagonists for atrial fibrillation - trends over 15 years.Current periprocedural management of ablation for atrial fibrillation in Europe: results of the European Heart Rhythm Association survey.Management of patients with atrial fibrillation by primary-care physicians in Germany: 1-year results of the ATRIUM registry.Gender differences in patients with atrial fibrillation.Comparison of stroke risk factors and outcomes in patients with English-speaking background versus non-English-speaking background.Darexaban (YM150), an oral direct factor Xa inhibitor, has no effect on the pharmacokinetics of digoxin.Structured care of patients with atrial fibrillation improves guideline adherence.Are atrial fibrillation guidelines altering management? A community based study.Improved persistence with non-vitamin-K oral anticoagulants compared with warfarin in patients with atrial fibrillation: recent Australian experience.
P2860
Q24197843-63D05E34-63ED-4D48-AC26-C40C8BE7885FQ24800847-ACC65EAF-4A1A-4DC2-B266-71BD94843FAEQ26991728-F468697A-9373-4588-843C-CA7254CCF15CQ28218125-F2DA6567-B13E-4326-AFB9-1B002D50DC85Q30559656-9C901F3F-2686-4025-9AE0-7F2DF7476228Q33265480-019C1B3F-9A7A-4016-B050-98483DA518ADQ33935409-5D21BD10-1DD7-4689-BDD2-F766615A11A1Q35226363-542A3145-FCC4-49AD-BB0E-8A72684F0C27Q36817630-F78A9620-2931-48E5-BF39-A6EAD4384D3FQ36982811-F6D88142-8372-49F8-97F3-09734FC7FBB2Q37115740-287E8CD8-90B6-4F49-A089-DF6D1F9C93D0Q37116033-E2D4BBD8-60D4-4D51-AF9B-DDB4725DA69BQ37137707-BB8B1C98-1100-4B02-820D-52D8DA1AC80EQ37375190-E83DFE3A-5803-40BB-8384-9220BB0B7E82Q37912899-BB02B804-ACA0-44EF-B683-FAF24434F29EQ39157217-D37427F2-8D6F-4563-9C16-40E6EEE77596Q39527946-85E73371-1730-4C27-8448-8046C6754FF0Q41816924-FB7FAF5D-28D3-4077-B99F-47B880BC6C31Q43530779-716E8E2D-C66A-4B42-B25A-9658245FBCBEQ43533823-40078993-1C0B-45CB-ADEE-9D437BEB9F2CQ43695319-D8FBE644-099B-479C-AA8C-419678FDBE0FQ43788136-CE5BAEB4-2F28-4100-B871-0254EC70F54CQ44105556-0BB353E2-B648-4632-B867-AC3D555B5055Q45086738-BD65599A-0AB4-4385-A34A-2DB650EB434FQ46153031-97451C33-B406-40B5-BC67-797D0F982587Q46223779-E5104E7E-A465-45FF-9A98-FDDD78AFE6C3Q46865870-249B8D38-B681-4F7C-8518-6D52DE8254BEQ54511916-6DBD4E37-129A-4736-9F56-A587349C7109
P2860
Management of atrial fibrillation: discrepancy between guideline recommendations and actual practice exposes patients to risk for complications
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Management of atrial fibrillat ...... ents to risk for complications
@ast
Management of atrial fibrillat ...... ents to risk for complications
@en
Management of atrial fibrillat ...... ents to risk for complications
@nl
type
label
Management of atrial fibrillat ...... ents to risk for complications
@ast
Management of atrial fibrillat ...... ents to risk for complications
@en
Management of atrial fibrillat ...... ents to risk for complications
@nl
prefLabel
Management of atrial fibrillat ...... ents to risk for complications
@ast
Management of atrial fibrillat ...... ents to risk for complications
@en
Management of atrial fibrillat ...... ents to risk for complications
@nl
P2093
P356
P1476
Management of atrial fibrillat ...... ents to risk for complications
@en
P2093
P304
P356
10.1053/EUHJ.2000.2300
P407
P577
2001-10-01T00:00:00Z